Flurbiprofen Axetil

Long-term Effects Secondary to Cancer Therapy in Adults

Peking University First HospitalPhase 4 / ApprovedDormant

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

0 Active assets in the Long-term Effects Secondary to Cancer Therapy in Adults cohort.

Asset / Sponsor	Phase	Rating
SUFENTANYL Peking University First Hospital	Phase 4	BB
DEXAMETHASONE Peking University First Hospital	Phase 4	BB
Irinotecan University of California, Davis	Phase 1/2	CCC
Carboplatin University of California, San Francisco		D
Cyclophosphamide University of California, San Francisco		D
Docetaxel University of California, San Francisco		D
TRASTUZUMAB University of California, San Francisco		D
Inno-206 University of California, San Francisco		D